Vicus Capital Gilead Sciences, Inc. Transaction History

Vicus Capital

$1.1 Billion
Q2 2024

A detailed history of Vicus Capital transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Vicus Capital holds 5,806 shares of GILD stock, worth $491,129. This represents 0.04% of its overall portfolio holdings.

Number of Shares

5,806

Previous 6,311 8.0%

Holding current value

$491,129

Previous $462,000 13.85%

% of portfolio

0.04%

Previous 0.04%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 23, 2024	SELL	$63.15 - $72.88 $31,890 - $36,804	-505 Reduced 8.0%	5,806 $398,000
Q1 2024 Apr 17, 2024	BUY	$71.58 - $87.29 $106,654 - $130,062	1,490 Added 30.91%	6,311 $462,000
Q4 2023 Feb 01, 2024	SELL	$73.27 - $83.09 $73,782 - $83,671	-1,007 Reduced 17.28%	4,821 $390,000
Q3 2023 Oct 23, 2023	BUY	$73.94 - $80.67 $53,236 - $58,082	720 Added 14.1%	5,828 $436,000
Q2 2023 Aug 17, 2023	BUY	$76.01 - $86.7 $106,109 - $121,033	1,396 Added 37.61%	5,108 $393,000
Q1 2023 May 02, 2023	SELL	$77.31 - $88.08 $22,033 - $25,102	-285 Reduced 7.13%	3,712 $307,000
Q4 2022 Feb 15, 2023	SELL	$62.32 - $89.47 $11,965 - $17,178	-192 Reduced 4.58%	3,997 $343,000
Q3 2022 Nov 08, 2022	BUY	$59.54 - $68.01 $28,579 - $32,644	480 Added 12.94%	4,189 $258,000
Q2 2022 Aug 10, 2022	BUY	$57.72 - $65.01 $13,333 - $15,017	231 Added 6.64%	3,709 $229,000
Q1 2022 May 11, 2022	BUY	$57.92 - $72.58 $15,522 - $19,451	268 Added 8.35%	3,478 $207,000
Q4 2021 Feb 10, 2022	BUY	$64.88 - $73.64 $208,264 - $236,384	3,210 New	3,210 $210,000
Q3 2021 Oct 14, 2021	SELL	$67.69 - $73.03 $220,127 - $237,493	-3,252 Closed	0 $0
Q2 2021 Aug 10, 2021	SELL	$63.47 - $69.35 $21,452 - $23,440	-338 Reduced 9.42%	3,252 $224,000
Q1 2021 May 04, 2021	BUY	$60.0 - $68.46 $215,400 - $245,771	3,590 New	3,590 $232,000
Q4 2020 Feb 01, 2021	SELL	$56.65 - $64.55 $272,996 - $311,066	-4,819 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$62.1 - $78.08 $115,381 - $145,072	-1,858 Reduced 27.83%	4,819 $305,000
Q2 2020 Aug 03, 2020	BUY	$72.34 - $84.0 $72,557 - $84,252	1,003 Added 17.68%	6,677 $514,000
Q1 2020 May 07, 2020	SELL	$62.63 - $80.22 $54,863 - $70,272	-876 Reduced 13.37%	5,674 $424,000
Q4 2019 Feb 04, 2020	SELL	$61.62 - $67.78 $35,000 - $38,499	-568 Reduced 7.98%	6,550 $426,000
Q3 2019 Nov 18, 2019	SELL	$62.51 - $69.0 $45,819 - $50,577	-733 Reduced 9.34%	7,118 $451,000
Q2 2019 Aug 08, 2019	SELL	$61.87 - $69.38 $22,830 - $25,601	-369 Reduced 4.49%	7,851 $530,000
Q1 2019 May 02, 2019	BUY	$62.53 - $70.05 $21,948 - $24,587	351 Added 4.46%	8,220 $534,000
Q4 2018 Feb 07, 2019	SELL	$60.54 - $79.0 $4,056 - $5,293	-67 Reduced 0.84%	7,869 $492,000
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $4,561 - $5,050	-64 Reduced 0.8%	7,936 $613,000
Q2 2018 Aug 02, 2018	SELL	$64.88 - $75.68 $165,249 - $192,756	-2,547 Reduced 24.15%	8,000 $567,000
Q1 2018 May 07, 2018	SELL	$72.84 - $88.8 $49,167 - $59,940	-675 Reduced 6.01%	10,547 $795,000
Q4 2017 Jan 25, 2018	SELL	$71.15 - $83.52 $19,495 - $22,884	-274 Reduced 2.38%	11,222 $804,000
Q3 2017 Oct 27, 2017	BUY	$72.11 - $85.47 $828,976 - $982,563	11,496	11,496 $931,000

Others Institutions Holding GILD

# of Institutions

1,880

Shares Held

1.02B

Call Options Held

12M

Put Options Held

8.96M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $106B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vicus Capital, based on Form 13F filings with the SEC.

News

Stay updated on Vicus Capital with notifications on news.

Account